title: Acute bleeding after bone marrow transplantation (BMT)- incidence and effect on survival. A quantitative analysis in 1,402 patients.
abstract: Acute bleeding after bone marrow transplantation (BMT) was investigated in 1,402 patients receiving transplants at Johns Hopkins Hospital between January 1, 1986 and June 30, 1995. Bleeding categorization was based on daily scores of intensity used by the blood transfusion service. Moderate and severe episodes were analyzed for bleeding sites. Analysis of the cause of death and the interval of the bleeding episode to outcome endpoints was recorded. Survival estimates were computed for 1,353 BMT patients. The overall incidence was 34%. Minor bleeding was seen in 10.6%, moderate bleeding was seen in 11.3%, and severe bleeding was seen in 12% of all patients. Fourteen percent of patients had moderate or severe gastrointestinal hemorrhage, 6.4% had moderate or severe hemorrhagic cystitis, 2.8% had pulmonary hemorrhage, and 2% had intracranial hemorrhage. Sixty-one percent had 1 bleeding site and 34.4% had more than 1 site. Moderate and severe bleeding was more prevalent in allogeneic (31%) and unrelated patients (62.5%) compared with autologous patients (18.5%). Significant distribution of incidence was found among the different diagnoses, but not by disease status in acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, Hodgkin's disease, and non-Hodgkin's lymphoma. Bleeding was associated with significantly reduced survival in allogeneic, autologous, and unrelated BMT and in each disease category except multiple myeloma. Survival was correlated with the bleeding intensity, bleeding site, and the number of sites. Although close temporal association was evident to mortality, bleeding was recorded as the cause of death in only the minority of cases compared with other toxicities after BMT (graft-versus-host disease, infections, and preparative regimen toxicity). Acute bleeding is a common complication after BMT that is profoundly associated with morbidity and mortality. Although bleeding was not a direct cause of death in the majority of cases, it has a potential prognostic implication as a predictor of poor outcome in clinical assessment of patients after BMT.
authors.affiliation: Johns Hopkins Oncology Center, Baltimore, MD 21287-8985, USA.
authors.forename: S
authors.initials: S
authors.lastname: Nevo
authors.forename: V
authors.initials: V
authors.lastname: Swan
authors.forename: C
authors.initials: C
authors.lastname: Enger
authors.forename: K J
authors.initials: KJ
authors.lastname: Wojno
authors.forename: R
authors.initials: R
authors.lastname: Bitton
authors.forename: M
authors.initials: M
authors.lastname: Shabooti
authors.forename: A K
authors.initials: AK
authors.lastname: Fuller
authors.forename: R J
authors.initials: RJ
authors.lastname: Jones
authors.forename: H G
authors.initials: HG
authors.lastname: Braine
authors.forename: G B
authors.initials: GB
authors.lastname: Vogelsang
mesh_terms: D000208:Acute Disease; D000328:Adult; D016026:Bone Marrow Transplantation / Q000009:adverse effects* / Q000401:mortality; D002648:Child; D002675:Child, Preschool; D005260:Female; D006470:Hemorrhage / Q000401:mortality; D006801:Humans; D007223:Infant; D008297:Male; D016019:Survival Analysis